Skip to content
akaturk Academic measurement
Search

Article detail · 2010 · article

Bortezomib a new therapeutic option for POEMS syndrome

ISSN0902-4441
YÖKSİS OpenAlex Open access · bronze Top 10%
Year2010
Citations54OpenAlex
Citations60Semantic Scholar
Percentile%93.3
FWCI3.811.00 = world average
Scopus (SJR)Q1
WoS (JCR)Q2

Data source split

  • YÖKSİSYÖKSİS article record
  • YÖKSİS venueEuropean Journal of Haematology
  • Catalog match (ISSN)European Journal of Haematology
  • OpenAlexOpenAlex enrichment (abstract, citations, topics)
  • Semantic Scholarcitation count (not merged with OpenAlex)

Abstract

OpenAlex English

OBJECTIVE: POEMS syndrome with its classical five findings (Polyneuropathy, Organomegaly, Endocrinopathy, M protein, and Skin changes) is a rare multisystem disease. Proinflammatory and proangiogenic cytokines play important roles in its pathogenesis. Treatment options are still debated. METHODS: We present a 65-year-old man with POEMS syndrome who was successfully treated with bortezomib. RESULTS: After seven cycles of this protocol, serum M protein level declined to normal range, and near-to-complete remission was achieved. His symptoms of polyneuropathy improved dramatically. CONCLUSION: Bortezomib may be an effective and safe therapeutic option for patients with POEMS syndrome.

Topics

Citations

OpenAlex cited_by_count. Not a WoS or Scopus citation count; those sources have no separate column here.

54citationsOpenAlex · cited_by_count (cache / database)

1 publications in the local catalog that cite this work (OpenAlex reference match; not the full global list).

  1. 2011 Complete Remission with a Combination of Lenalidomide Cyclophosphamide and Prednisolone in a Patient with Incomplete POEMS SyndromeCitations 9 · OpenAlex

Authors

5
  1. IŞIK ATAGÜNDÜZ 1
  2. Tezcan Hakan 2
  3. MUSTAFA ÇETİNER 3
  4. OZAN KOCAKAYA İSTANBUL SAĞLIK VE TEKNOLOJİ ÜNİVERSİTESİ 4
  5. Bayik Mahmut 5